AI Analysis | Feedback

Amgen for next-generation RAS pathway inhibitors.

A specialized precision oncology company, similar to Blueprint Medicines, but focused on the complex RAS pathway.

AI Analysis | Feedback

• **RMC-4630**: An SHP2 inhibitor in Phase 1/2 clinical trials for solid tumors.
• **RMC-5845**: A selective inhibitor of SOS1, a protein involved in RAS activation.
• **RMC-5552**: A hyperactivated selective inhibitor of mTORC1 signaling in tumors.
• **RMC-6291**: A mutant-selective inhibitor targeting KRASG12C(ON) and NRASG12C(ON).
• **RMC-6236**: A RAS-selective inhibitor designed to target multiple RAS(ON) variants.
• **RAS(ON) Inhibitors**: A class of drug candidates targeting KRASG13C(ON) and KRASG12D(ON) mutations.

AI Analysis | Feedback

Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company. At this stage of its development, the company is primarily focused on the research and development of drug candidates and does not yet have approved products for commercial sale to individuals or healthcare providers.

Based on the provided description, Revolution Medicines' major customer or strategic partner identified is:

• Sanofi (NYSE: SNY)

This relationship is described as a collaboration agreement for the research and development of SHP2 inhibitors, including RMC-4630. In such agreements, the partner company typically provides funding, resources, or future milestone payments, effectively acting as a customer for the intellectual property and development capabilities of Revolution Medicines.

AI Analysis | Feedback

AI Analysis | Feedback

Mark A. Goldsmith, President, Chief Executive Officer, and Board Chairman

Dr. Goldsmith has served as President, Chief Executive Officer, and Board Chairman of Revolution Medicines since November 2014, and was appointed Chair of the Board in 2020. He is recognized as a proven biotechnology leader with a deep scientific background and broad operating expertise. Prior to his role at Revolution Medicines, Dr. Goldsmith was a Partner with Third Rock Ventures, a life sciences venture capital firm, from 2013 to 2015, and a Venture Partner from 2012 to 2013, indicating a pattern of managing companies backed by private equity firms. He previously served as President and Chief Executive Officer of Constellation Pharmaceuticals from 2009 to 2012, and as Chairman from 2012 to 2016 and 2017 to 2021, through its acquisition by MorphoSys AG. He also was the first CEO of Global Blood Therapeutics and Nurix, Inc. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology and practiced medicine on the faculty of the University of California, San Francisco. He has co-authored 85 scientific publications and is a co-inventor on multiple issued patents.

Jack Anders, Chief Financial Officer

Jack Anders has served as Chief Financial Officer of Revolution Medicines since September 2022, having joined the company in August 2018. He previously held positions within Revolution Medicines as Senior Vice President, Finance (March 2021 to September 2022) and Vice President, Finance (August 2018 to March 2021). Before joining Revolution Medicines, Mr. Anders spent 12 years at Depomed, Inc., a specialty pharmaceutical company, from 2006 to July 2018, most recently as Vice President of Finance. At Depomed, he was instrumental in establishing financial planning and analysis, commercial finance, accounting operations, and external reporting functions. His contributions supported multiple product launches, product acquisitions, divestitures, and capital raises totaling over $1 billion. Mr. Anders also held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo!, and Novellus Systems. He began his career in the life sciences practice at PricewaterhouseCoopers LLP and is a former certified public accountant.

Margaret Horn, Chief Operating Officer

Margaret Horn serves as the Chief Operating Officer of Revolution Medicines. She joined the company in October 2018. Ms. Horn is described as a seasoned corporate executive with extensive experience in both small and large companies.

Stephen Kelsey, President of Research and Development

Stephen Kelsey is the President of Research and Development at Revolution Medicines, a role he has held since February 2017. He is responsible for leading the core scientific innovation and pipeline expansion for the company.

Alan Sandler, Chief Development Officer

Alan Sandler, M.D., was appointed as Chief Development Officer of Revolution Medicines in September 2025. He joined Revolution Medicines from ALX Oncology, where he served as Chief Medical Officer. Prior to ALX Oncology, Dr. Sandler was Executive Vice President and Chief Medical Officer at Mirati Therapeutics, through its acquisition by Bristol Myers Squibb. He previously held positions as President and Head of Global Development, Oncology at Zai Lab Limited, and senior leadership roles at Genentech, a member of the Roche Group.

AI Analysis | Feedback

The key risks to Revolution Medicines (RVMD) are:

1. Clinical Trial Outcomes and Regulatory Approval: Revolution Medicines' success is heavily reliant on the successful outcome of its ongoing and future clinical trials for its pipeline of drug candidates, including daraxonrasib, zoldonrasib, and other RAS inhibitors. Drug development inherently carries a high risk of failure, and negative, mixed, or delayed results from these trials could significantly impact the company's prospects, leading to substantial adverse effects on its stock price and commercial viability. Furthermore, even with positive clinical data, there is no guarantee that regulatory bodies will grant approvals for its therapies, or that prior promising results will be replicated in subsequent larger studies.

2. High Cash Burn and Future Funding Needs: As a clinical-stage biotechnology company without any marketed products, Revolution Medicines currently generates no revenue and incurs significant and rapidly escalating operating losses and negative cash flow due to extensive research and development expenditures. While the company has a substantial cash position and has secured additional financing, persistent high cash burn erodes equity and necessitates ongoing funding. This increases the risk of future equity dilution for existing shareholders if clinical development setbacks or delays in regulatory approvals prolong the timeline to commercialization and revenue generation.

3. Intense Competition: Revolution Medicines operates within the highly competitive oncology market, particularly in the RAS inhibitor space. Numerous pharmaceutical and biotechnology companies are developing similar targeted therapies for RAS-addicted cancers. The emergence of competitors with treatments that demonstrate superior efficacy, safety, or that reach the market sooner could significantly limit Revolution Medicines' potential market share, pricing power, and future revenue streams.

AI Analysis | Feedback

AI Analysis | Feedback

Revolution Medicines (RVMD) is developing therapies for several oncology targets, each with a distinct addressable market.

RMC-4630 (SHP2 inhibitor for solid tumors, such as gynecologic and colorectal cancer tumors)

• While a specific global market size for SHP2 inhibitors was not readily available, the market is expected to grow, with North America anticipated to hold a significant revenue share.
• For **Colorectal Cancer**, the global market size was estimated at USD 11.5 billion in 2022 and is expected to grow to USD 16.7 billion by 2030. Another report valued the global colorectal cancer market at USD 13 billion in 2023, projecting it to reach USD 20 billion by 2032. North America held 42.6% of the global colorectal cancer therapeutics market in 2022. The global metastatic colorectal cancer market is projected to reach USD 19.06 billion by 2035 from USD 6.78 billion in 2024.
• For **Gynecological Cancers**, the global drugs market size is estimated at USD 17.65 billion in 2024 and is projected to reach approximately USD 29.58 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2034. North America dominated the gynecological cancer drugs market revenue shares in 2024.

RMC-5845 (SOS1 inhibitor for RAS-addicted cancers)

• The global **SOS1 Inhibitors** market size was valued at USD 0.29 billion in 2024 and is projected to reach USD 2.15 billion by 2033, expanding at an impressive CAGR of 24.7%. North America accounts for over 45% of global revenues in 2024.
• For the broader **RAS-Targeting Drugs for Precision Oncology** or **Ras Acting Agents Market**, the global market size is anticipated to grow from USD 2.5 billion in 2023 to an estimated USD 7.8 billion by 2032, at a CAGR of 13.4%. The United States market for Ras acting agents is projected to grow at a CAGR of 12.8% over the forecast period, reaching an estimated USD 3.5 billion by 2032.

RMC-5552 (mTORC1 inhibitor for hyperactivated mTORC1 signaling in tumors)

• The global **mTOR Inhibitors** market size was valued at USD 9.97 billion in 2023 and is projected to reach USD 16.82 billion by 2032, growing at a CAGR of 5.98%. Another report indicates the global market, valued at USD 7.2 billion in 2024, is expected to appreciate to USD 11.5 billion by 2030, with a robust CAGR of 8.1%. The U.S. mTOR Inhibitors Market, representing 31% of the global revenue, was valued at approximately USD 2.23 billion in 2024 and is expected to expand to nearly USD 3.44 billion by 2030.

RMC-6291 (mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON)), RMC-6236 (RAS-selective inhibitor of multiple RAS(ON) variants), and RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON)

• The **KRAS Inhibitors Market** in the 7 Major Markets (United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) was valued at approximately USD 526 million in 2025 and is projected to reach USD 7,847 million by 2034, expanding at an impressive CAGR of 35%. The United States captured the highest KRAS inhibitors market size in 2024, accounting for nearly 70% of the total market share in the 7 Major Markets. The global KRAS inhibitor drug market size was valued at USD 2.43 billion in 2025 and is expected to reach USD 10.37 billion by 2033, at a CAGR of 19.90%.
• Specifically, **KRAS G12C** remains the most commercially validated segment, accounting for roughly 70% of current KRAS inhibitor market revenue (2024 estimate).
• **KRAS G12D** is identified as a rising target, particularly in colorectal and pancreatic cancers, and is expected to drive significant growth.
• **Pan-RAS/multiple RAS(ON) variants** (like RMC-6236) are noted for their "tremendous market potential due to the broad target patient population they can address." Revolution Medicines is actively researching pan-RAS therapies.

AI Analysis | Feedback

• Regulatory Approval and Commercial Launch of Daraxonrasib (RMC-6236): Revolution Medicines' lead drug candidate, daraxonrasib, a RAS(ON) multi-selective inhibitor, is currently in multiple Phase 3 clinical trials for pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC). The drug has received FDA Breakthrough Therapy Designation and a Commissioner's National Priority Voucher, which could potentially accelerate its regulatory review and market entry. Positive data readouts from pivotal trials are anticipated in the first half of 2026, paving the way for potential regulatory approval and subsequent commercial sales, which would represent a significant new revenue stream for the company.
• Advancement and Pivotal Trials of Zoldonrasib (RMC-9805) and Elironrasib (RMC-6291): The company is progressing other mutant-selective RAS(ON) inhibitors, including zoldonrasib (KRAS G12D-selective) and elironrasib (KRAS G12C-selective). Zoldonrasib has demonstrated encouraging clinical activity in PDAC and NSCLC, and Revolution Medicines plans to initiate one or more pivotal combination trials incorporating either zoldonrasib or elironrasib in 2026. Successful progression through late-stage clinical development and potential accelerated approvals for these candidates would significantly bolster future revenue expectations and market opportunities.
• Expansion into Earlier Lines of Therapy and Combination Regimens: Revolution Medicines is strategically focused on expanding its lead candidates into earlier lines of treatment and developing combination therapies across various tumor types, including pancreatic, lung, and colorectal cancers. This approach broadens the addressable patient population and enhances the market potential for their RAS(ON) inhibitors, such as evaluating daraxonrasib as a first-line treatment for metastatic PDAC and exploring combinations with standard-of-care treatments or other investigational agents.
• Leveraging Strategic Partnerships and Funding: The strategic partnership with Royalty Pharma provides access to up to $2.0 billion in committed capital, with the first $250 million tranche already received. This substantial funding enhances the company's financial flexibility, enabling aggressive investment in clinical development and commercial preparation for its pipeline assets. While not direct product revenue, this capital is crucial for accelerating the clinical programs and commercial readiness, thereby facilitating future product launches and revenue generation within the specified timeframe.

AI Analysis | Feedback

Share Issuance

• Revolution Medicines successfully closed an upsized public offering in December 2024, raising $862.5 million in gross proceeds through the issuance of 16,576,088 shares of common stock and pre-funded warrants to purchase 2,173,917 shares.
• The company's annual net total equity issued/repurchased for 2023 was $1.233 billion, marking a 309.18% increase from 2022.
• Revolution Medicines' diluted average shares outstanding significantly increased from $72.8 million in 2021 to $189.2 million in Q3 2025, with a 48.24% increase in 2024.

Inbound Investments

• In June 2025, Revolution Medicines entered into a flexible funding agreement with Royalty Pharma for up to $2 billion, composed of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.
• The company received the first $250 million tranche of the synthetic royalty funding from Royalty Pharma at the closing of the agreement in June 2025.

Capital Expenditures

• Revolution Medicines' capital expenditures were $6.53 million in 2021, $11 million in 2022, $7.73 million in 2023, $10 million in 2024, and $16 million in 2025.
• In Q4 2025, capital expenditures amounted to $1.9 million, primarily directed towards funding long-term assets and infrastructure.
• For 2026, the company projects GAAP operating expenses to be between $1.6 billion and $1.7 billion, driven by the progression and expansion of clinical development programs and increased commercial preparation activities.